Shi Zijun, Kuai Mengmeng, Li Baohua, Akowuah Carlos Frimpong, Wang Zhenyu, Pan Ye, Tang Min, Yang Xiaoyue, Lü Peng
School of Life Sciences, Jiangsu University, Zhenjiang 212013, China.
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai 200030, China.
Cytokine. 2025 May;189:156908. doi: 10.1016/j.cyto.2025.156908. Epub 2025 Mar 5.
Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis, playing a pivotal role in both physiological and pathological processes. It promotes the formation of new blood vessels and activates downstream signaling pathways that regulate endothelial cell function. This review highlights recent advancements in the understanding of VEGF's molecular structure and its isoforms, as well as their implications in disease progression. It also explores the mechanisms of VEGF inhibitors. While VEGF inhibitors show promise in the treatment of cancer and other diseases, their clinical use faces significant challenges, including drug resistance, side effects, and complex interactions with other signaling pathways. To address these challenges, future research should focus on: (i) enhancing the understanding of VEGF subtypes and their distinct roles in various diseases, supporting the development of personalized treatment strategies; (ii) developing combination therapies that integrate VEGF inhibitors with other targeted treatments to overcome resistance and improve efficacy; (iii) optimizing drug delivery systems to reduce off-target effects and enhance therapeutic outcomes. These approaches aim to improve the effectiveness and safety of VEGF-targeted therapies, offering new possibilities for the treatment of VEGF-related diseases.
血管内皮生长因子(VEGF)是血管生成的关键调节因子,在生理和病理过程中都起着关键作用。它促进新血管的形成,并激活调节内皮细胞功能的下游信号通路。本综述重点介绍了对VEGF分子结构及其异构体的最新认识,以及它们在疾病进展中的影响。它还探讨了VEGF抑制剂的作用机制。虽然VEGF抑制剂在癌症和其他疾病的治疗中显示出前景,但其临床应用面临重大挑战,包括耐药性、副作用以及与其他信号通路的复杂相互作用。为应对这些挑战,未来的研究应集中于:(i)加强对VEGF亚型及其在各种疾病中不同作用的理解,支持个性化治疗策略的开发;(ii)开发将VEGF抑制剂与其他靶向治疗相结合的联合疗法,以克服耐药性并提高疗效;(iii)优化药物递送系统,以减少脱靶效应并增强治疗效果。这些方法旨在提高VEGF靶向治疗的有效性和安全性,为治疗与VEGF相关的疾病提供新的可能性。